OptiNose (OPTN) Company Overview

Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose's common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose's existing trading symbol “OPTN.”

Company reports Q3 2024 XHANCE net revenue of $20.4 million , an increase of 3% compared to Q3 2023

YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer.

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society.

OptiNose, Inc. (NASDAQ:OPTN ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief Commercial Officer Conference Call Participants Schuyler van den Broek - Piper Sandler Thomas Flaten - Lake Street Capital Markets Operator Hello, and welcome to the OptiNose Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

OptiNose (OPTN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.

OptiNose, Inc. (NASDAQ: OPTN) will be holding its Q1 2024 Results Conference Call on May 15, 2024 at 10:00 AM ET. Company representatives include Jonathan Neely, VP of IR & Business Development, and Dr. Ramy Mahmoud, CEO. Conference call participants include analysts from Lake Street Capital Markets, Piper Sandler, Jefferies, and H.C. Wainwright. The operator begins the call by thanking participants for joining.

Optinose (NASDAQ: OPTN), a pharmaceutical company specializing in patients cared for by ear, nose, and throat (ENT) and allergy specialists, revealed today that its management team will be giving a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.